Arcus Biosciences Price to Sales Ratio 2017-2022 | RCUS

Historical PS ratio values for Arcus Biosciences (RCUS) over the last 10 years. The current P/S ratio for Arcus Biosciences as of February 03, 2023 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Arcus Biosciences P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2023-02-03 20.51 3.49
2022-09-30 26.16 $5.88 4.45
2022-06-30 25.34 $5.55 4.56
2022-03-31 31.56 $5.32 5.94
2021-12-31 40.47 $5.20 7.78
2021-09-30 34.87 $0.58 59.63
2021-06-30 27.46 $1.44 19.06
2021-03-31 28.08 $1.34 20.94
2020-12-31 25.96 $1.24 20.95
2020-09-30 17.14 $1.29 13.30
2020-06-30 24.74 $0.34 73.23
2020-03-31 13.88 $0.34 40.61
2019-12-31 10.10 $0.34 29.49
2019-09-30 9.10 $0.17 55.11
2019-06-30 7.95 $0.23 35.26
2019-03-31 12.49 $0.21 58.12
2018-12-31 10.77 $0.31 35.15
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.532B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.721B 9.45
GSK (GSK) United Kingdom $71.915B 9.49
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.215B 19.14
Ginkgo Bioworks Holdings (DNA) United States $4.249B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Biohaven (BHVN) United States $1.307B 0.00
Emergent Biosolutions (EBS) United States $0.726B 5.71
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Ambrx Biopharma (AMAM) United States $0.071B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.023B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00